Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab maintenance and long-term safety study in ulcerative colitis
NL-OMON59969Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of risankizumab in autoimmune colitis (6 arms), sponsored by AbbVie Inc. Started Oct 2018; status: active, not recruiting.
02
Drugs
risankizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON59969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59969.